ProMIS Neurosciences’ PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies
Go back to ProMIS Neurosciences’ PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies| Amorfix Life Sciences Ltd Common Shares (AMEX: ARFXF) | Delayed: 0.10 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.10 | 52 Week High | $0.16 | |||
| Open | $11.33 | 52 Week Low | $0.03 | |||
| Day High | $0.10 | P/E | N/A | |||
| Day Low | $0.10 | EPS | $0.00 | |||
| Volume | 3,285 | |||||
| Imperial Petroleum, Inc. (NASDAQ: PMN) | Delayed: 12.60 -0.3 (2.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.90 | 52 Week High | $0.05 | |||
| Open | $13.03 | 52 Week Low | $0.05 | |||
| Day High | $13.46 | P/E | N/A | |||
| Day Low | $12.48 | EPS | $0.00 | |||
| Volume | 24,087 | |||||
